http://rdf.ncbi.nlm.nih.gov/pubchem/reference/13644499

Outgoing Links

Predicate Object
contentType Journal Article|Research Support, Non-U.S. Gov't
issn 2573-8348
issueIdentifier 11
pageRange e1613-
publicationName Cancer reports (Hoboken, N.J.)
startingPage e1613
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_634e3b5dadc053b60b99fda0b87acb04
bibliographicCitation Sekiguchi S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Okamoto R, Kurosaki M, Izumi N. Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy. Cancer Rep (Hoboken). 2022 Nov;5(11):e1613. PMID: 35302279; PMCID: PMC9675392.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cefae10e8abaff61db350977359dc03b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7d18a01caa28d6c89e3063cccf690305
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fa2d24ed2fc63d6be6003c292b5b7cb0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cd01e26077bbf5d93b250df49dd854e1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ad0ea432e5c5882a348a3ddd250de4a6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_776ebbd39085745338f924cb82c38eb7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5984-1064
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_97faeb4f8dbc4b733ebbea22a30d3e5a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ed6c8a4e9fbec2ebe20516d95955352
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b7fa944fd7e2e797d4e193c9025c0e9a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6048705f535b9d4825d1baa6d1fec6b5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_024c49e372b2f1c09f0c899e79614d36
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_24a107590e5e4bbc0c00f0c7a7810eca
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_35b0a7a31006398e73b050b5067464cc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f235a5221f442b11184cd18a6be24a6f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cdcc45c43759de020bc1f72be1910b29
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2a98fa26b25bfba19fc20adc1d2ac71f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_841a2f89d90ac24ae5beebb196524d8e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_037d71dc5ae2ccce2e1a820a1c2d7183
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_26e8dfb5429e93a402188a0640bc8c7d
date 2022-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/PMC9675392
https://doi.org/10.1002/cnr2.1613
https://pubmed.ncbi.nlm.nih.gov/35302279
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/48635
https://portal.issn.org/resource/ISSN/2573-8348
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
discusses http://id.nlm.nih.gov/mesh/M0446095
http://id.nlm.nih.gov/mesh/M0575909
http://id.nlm.nih.gov/mesh/M0001483
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D006528Q000188
http://id.nlm.nih.gov/mesh/D006528Q000175
http://id.nlm.nih.gov/mesh/D008113Q000188
http://id.nlm.nih.gov/mesh/D000970Q000627
hasSubjectTerm http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D000077157
http://id.nlm.nih.gov/mesh/D015577
http://id.nlm.nih.gov/mesh/D000368
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID216239
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9823820
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7998
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fadc3c8509db129e10ef4cfccf6efc5d
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_95d926625e5919a35cb6aa367ba7b069
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f45a1981a993269f904dc188447f840b
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280352
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_73717aafac1e7701dab0fa02b8936926

Total number of triples: 58.